ASML Holding NV vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines ASML Holding NV and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching ASML Holding NV on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between ASML Holding NV and F. Hoffmann-La Roche AG is widest.

On the headline numbers, ASML Holding NV reports annual revenue of $35.3B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $268.0B and $327.5B. ASML Holding NV is headquartered in Netherlands and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

ASML Holding NV: ASML makes money by selling lithography systems and providing installed-base service, upgrades, software, and field options. Its EUV monopoly creates unusually high strategic importance within the global chip supply chain.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

ASML Holding NV and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between ASML Holding NV and F. Hoffmann-La Roche AG.

ASML Holding NV business model: Building one requires components sourced from more than 5,000 suppliers across 16 countries, assembled through a process so intricate that delivery, installation, and commissioning at a customer's fabrication plant takes months. EUV systems represent the apex of ASML's product portfolio and the locus of its pricing power. Instead, ASML sells performance upgrades — enhanced throughput, improved overlay accuracy, expanded process windows — as separately licensed software and hardware packages that customers purchase over the machine's operational lifetime. ASML's pricing power is extraordinary by any industrial standard, and it derives directly from the company's monopoly position. This allows ASML to maintain gross margins on EUV systems that consistently exceed 50 percent and to set pricing that reflects the extraordinary economic value the equipment creates for customers. The problem is, ASML captures a small but growing fraction of this value through its pricing. China's share of ASML's total revenue, which reached approximately 29 percent in the first half of 2023, has been progressively curtailed since the Dutch government declined to renew ASML's export license for EUV systems in 2019. Each new generation of EUV technology commands higher pricing, drives higher service revenue, and further widens the technological gap between ASML and any theoretical competitor.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of ASML Holding NV stack up against those of F. Hoffmann-La Roche AG.

ASML Holding NV competitive advantage: This service business is characterized by very high switching costs: a chipmaker cannot simply swap out lithography equipment mid-production without catastrophic disruption. The company's headquarters in Veldhoven, adjacent to the Dutch city of Eindhoven, reflects its roots in the Philips industrial ecosystem that made the southern Netherlands a European technology hub in the twentieth century. The physics challenges, the optical engineering requirements, and the supplier ecosystem limitations that China faces are not primarily financial obstacles; they are time and knowledge obstacles that money alone cannot solve on any commercially relevant timeline. ASML's competitive advantage is perhaps the most formidable in the global technology industry, resting on a combination of accumulated technological know-how, supplier ecosystem lock-in, customer switching costs, and regulatory moats that collectively make replication by any competitor — whether private, state-sponsored, or otherwise — extraordinarily difficult. The technological core of ASML's advantage is its mastery of EUV lithography, a technology that the company spent over 20 years and billions of dollars developing before shipping its first commercial EUV machine in 2017. The Carl Zeiss SMT relationship deserves particular emphasis as a competitive moat. ASML's customer relationships also create powerful demand-side moats. This technical advantage was real but not significant, and ASML spent its first several years fighting for every customer order, often competing on price to compensate for its lack of brand recognition.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Future prospects matter as much as current results. The growth strategies below explain how ASML Holding NV and F. Hoffmann-La Roche AG each plan to expand from here.

ASML Holding NV growth strategy: ASML's growth strategy centers on EUV capacity, High-NA EUV adoption, installed-base service upgrades, deep supplier coordination, and long-term demand from leading-edge logic and memory customers.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

A closer look at the financial trajectory of ASML Holding NV and F. Hoffmann-La Roche AG rounds out the comparison.

ASML Holding NV: ASML reported EUR32.7B in FY2025 total net sales, EUR9.6B in net income, a 52.8% gross margin, and EUR38.8B of backlog at year-end. Using CorpDigest's USD convention, those figures are shown as about $35.3B of revenue and $10.4B of net income. The key financial drivers are EUV system demand, DUV resilience, installed-base services, High-NA adoption, and export-control limits.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.